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Abstract
Background: Heart failure affects millions of elderly and is a major cause for hospitalization and death. A
large percentage of these patients will present with a prolonged QRS interval. This lag between the firing of
the right and left ventricles can make the heart inefficient, causing poor perfusion. Patients with a prolonged
QRS generally do not respond well to the current pharmacological treatments available and continue to have
worsening symptoms and progression of their disease. Cardiac resynchronization therapy attempts to
stimulate both ventricles simultaneously, with an implantable device, and thereby increasing the heart’s
output.
Method: An exhaustive search of available medical literature was performed using PubMed, Web of Science,
Cochrane, the National Clinical Trials Registry and CINHAL databases looking for studies on mortality and
morbidity of cardiac resynchronization therapy compared to pharmacological therapy. Using the key words
‘Heart Failure’, ‘Cardiac Resynchronization’, ‘Moderate’, ‘Mortality’ and ‘Death’, individually and in
combination. The search was limited to human subjects, full text availability, the English language and articles
from 2000 to 2010.
Results: The search revealed three randomized controlled trials with an extension of one of the three trials.
All the studies found a significant decrease of mortality and morbidity with the use of cardiac synchronization
therapy. Every one of the three also noted a higher rate of adverse events, secondary to implantation,
associated with this therapy.
Conclusion: By performing a systematic review using GRADE to evaluate the quality of evidence, it was
determined that cardiac-resynchronization therapy appreciably decreased the rate of death and
hospitalizations over optimal pharmacological care and should be considered for patients with a prolonged
QRS associated with heart failure.
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ABSTRACT 
 
Background:  Heart failure affects millions of elderly and is a major cause for 
hospitalization and death. A large percentage of these patients will present with a 
prolonged QRS interval. This lag between the firing of the right and left ventricles 
can make the heart inefficient, causing poor perfusion. Patients with a prolonged 
QRS generally do not respond well to the current pharmacological treatments 
available and continue to have worsening symptoms and progression of their 
disease. Cardiac resynchronization therapy attempts to stimulate both ventricles 
simultaneously, with an implantable device, and thereby increasing the heart’s 
output. 
 
Method:  An exhaustive search of available medical literature was performed 
using PubMed, Web of Science, Cochrane, the National Clinical Trials Registry 
and CINHAL databases looking for studies on mortality and morbidity of cardiac 
resynchronization therapy compared to pharmacological therapy. Using the key 
words ‘Heart Failure’, ‘Cardiac Resynchronization’, ‘Moderate’, ‘Mortality’ and 
‘Death’, individually and in combination. The search was limited to human 
subjects, full text availability, the English language and articles from 2000 to 
2010. 
 
Results:  The search revealed three randomized controlled trials with an 
extension of one of the three trials. All the studies found a significant decrease of 
mortality and morbidity with the use of cardiac synchronization therapy. Every 
one of the three also noted a higher rate of adverse events, secondary to 
implantation, associated with this therapy. 
 
Conclusion:  By performing a systematic review using GRADE to evaluate the 
quality of evidence, it was determined that cardiac-resynchronization therapy 
appreciably decreased the rate of death and hospitalizations over optimal 
pharmacological care and should be considered for patients with a prolonged 
QRS associated with heart failure. 
 
Keywords:  Heart Failure, Cardiac Resynchronization, Moderate, Mortality and 
Death 
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INTRODUCTION 
Background 
Heart failure (HF) is primarily a disease of the elderly. Approximately 75% 
of hospital admissions for HF are for persons greater than 65 years old (Golding, 
J., 2010). It affects approximately 5 million people in the US and more than 20 
million people worldwide (Golding, 2010; Mann, D., 2008).  
The eventual outcome of most cardiac disease process is HF. Coronary 
artery disease (CAD) and hypertension contributes 80% of the total cases of HF 
(Golding, 2010). This situation is likely to worsen as a large cohort, the Baby 
boomers, moves into the later stages of life. The near epidemic proportions of 
hypertension, CAD and obesity further exacerbate this situation. The financial 
burden is staggering. Currently, more Medicare dollars are spent to diagnose and 
treat heart failure than any other medical condition (Golding, 2010). 
Heart failure is considered a progressive disease. It begins when the heart 
muscle or nerve pathway becomes compromised by either an abrupt event, such 
as a myocardial infarction or insidiously, by volume overload. No matter how the 
damage is done, the once efficient pump becomes out of balance and begins to 
fail, thereby loosing its ability to deliver enough blood to meet the body’s needs. 
As the heart efficiency decreases, there is correlating increase in the symptoms.  
The disease may present with weakness, nocturnal nonproductive cough, 
orthopnea, paroxysmal nocturnal dyspnea, edema, cyanosis and anxiety. The 
cardinal symptoms are fatigue and shortness of breath on exertion (Mann, 2008), 
particularly with left heart failure. These may be the only presenting symptoms. A 
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comprehensive evaluation will be needed, including a thorough history and 
physical exam, chest x-ray, a complete serum work up and an Echocardiogram, 
to measure the ejection fraction (EF). EF is the amount of blood that the 
ventricles expel with each beat (Normal EF is 55 – 70%).  
The New York Heart Association (NYHA) classifies HF, in a four-tiered 
scale, by the severity of symptoms (Appendix A, Table 1). A patient with 
moderate HF would have a marked limitation of physical activity. The patient 
would also be comfortable at rest, but less than ordinary activity causes fatigue, 
palpitation, or dyspnea. Though, this classification system is very subjective, it 
has withstood the test of time and continues to be widely applied to patients with 
HF (Mann, 2008).  
There are approximately one-third of Heart Failure patients, with a 
decreased Ejection Fraction and symptomatic HF (NYHA class III-IV), who will 
manifest a QRS duration greater than 120 ms (Mann, 2008). This prolonged 
interval is associated with a poor prognosis (Pires, 2006). These patients 
respond poorly to conventional therapies and have frequent exacerbations and 
associated hospitalizations.  
A therapy that could be used to reduce hospitalizations and mortality is 
Cardiac Resynchronization. Over the last decade there have been several 
randomized controlled studies conducted on Cardiac-Resynchronization therapy 
(CRT). CRT uses an implanted device that stimulates both ventricles of the heart 
near-simultaneously.  By stimulating it in this manner, there is an improved 
coordination of contraction and a reduction of the severity of mitral regurgitation 
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occurs. CRT has shown promising results. 
Purpose of Study 
This paper will perform a systematic review using GRADE to evaluate the 
quality of evidence and answer the question: In a 65 year old patient, with 
moderate left sided heart failure and a prolonged QRS, does cardiac 
resynchronization therapy decrease mortality? 
 
METHOD 
 
An extensive literature search was performed using PubMed, Web of 
science, Cochrane, the National Clinical Trials Registry and CINHAL. These 
databases were accessed through the Pacific University Library system. The 
keywords searched included ‘Heart Failure’, ‘Cardiac Resynchronization’, 
‘Moderate’, ‘Mortality’ and ‘Death’, individually and in combination. The search 
was limited to human subjects, full text availability, the English language and 
articles from 2000 to 2010.  
This produced 49 articles. Only randomized controlled trials were 
reviewed, resulting in five reports addressing the effect of cardiac-
resynchronization therapy on patients with heart failure as it relates to mortality 
and met the inclusion and exclusion criteria for the systematic review. Of the five 
published articles found, four were randomized controlled trials and one was a 
follow-up of one of the previously mentioned trials. After a thorough search and 
review, it was noted that one of the four studies was included in a meta-analysis 
performed in 2002; therefore this article was excluded from the review.  
RESULTS  
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Bristow, et al. (2004) published a randomized controlled trial titled, the 
Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure 
(COMPANION). The COMPANION trial looked at 1520 patients who had 
advanced heart failure, NYHA Class III or IV, a left ventricle ejection fraction of 
35% or less, a QRS interval of at least 120 msec., no clinical indication for a 
pacemaker or implantable defibrillator, and a hospitalization for the treatment of 
heart failure or the equivalent in the preceding 12 months.   
The COMPANION patients were randomly assigned in a 1:2:2 ratio 
(Bristow et al., 2004). One group received optimal pharmacologic therapy, which 
included diuretics, angiotensin converting enzyme inhibitors, beta-blockers, and 
spironolactone. The next group received optimal pharmacologic therapy along 
with cardiac-resynchronization therapy with the implantation of a pacemaker. The 
final group received optimal pharmacologic therapy with the implantation of a 
pacemaker–defibrillator. The follow-up was 11.9 months in the pharmacologic-
therapy group, 16.2 months in the pacemaker group and 15.7 months in the 
pacemaker–defibrillator group (p<0.001 for the comparison with the 
pharmacologic therapy group).  
In the pacemaker or the pacemaker–defibrillator group, commercially 
available units and leads were used for right atrial pacing and right ventricular 
pacing or for pacing with defibrillation. An over-the-wire lead was placed into a 
distal branch of the coronary sinus vein for left ventricular stimulation. A 
proprietary algorithm was used to program the atrioventricular delay. The final 
pacing set for both devices settings were chamber paced: ventricle, chamber 
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sensed: both and, response:  both triggering and inhibiting functions exist. The 
lower rate was set below the patient’s lowest intrinsic heart rate.  
The study’s primary outcome was death or hospitalization (Appendix B, 
Table 2). Bristow et al. (2005) compared optimal pharmacological therapy alone 
to cardiac-resynchronization therapy with a pacemaker and found a decreased 
risk of death or hospitalization (hazard ratio, 0.81; p = 0.014). The cardiac-
resynchronization therapy with a pacemaker–defibrillator also decreased the risk 
of the primary outcome (hazard ratio, 0.80; p=0.01). As far as the risk of the 
combined end point of death from, or hospitalization for, heart failure, when 
compared to the pharmacologic-therapy group, there was a reduction of 34% 
(p<0.002) in the CRT group and of 40% (p<0.001) in the pacemaker–defibrillator 
group. Bristow et al. (2004) concluded CRT decreased the risk of death from any 
cause or first hospitalization and, in combination with an implantable defibrillator, 
there was a significant reduction in mortality. 
In 2005, Cleland et al. (2005) published a report of their randomized 
controlled trial, The Cardiac Resynchronization - Heart Failure (CARE-HF) 
involving 813 patients with New York Heart Association Class III or IV heart 
failure, a left ventricular ejection fraction of less than 35%, and a QRS interval of 
at least 120 msec. Additionally, an aortic pre-ejection delay of greater than 140 
msec., an interventricular mechanical delay of more than 40 msec., or a delayed 
activation of the posterolateral left ventricular wall was required for inclusion. The 
study excluded patients who had had a major cardiovascular event in the 
previous six weeks, those who had conventional indications for a pacemaker or 
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an implantable defibrillator, those with heart failure requiring continuous 
intravenous therapy and patients with atrial arrhythmias.  
The randomization was done in a stratified manner according to the 
patient’s NYHA class by quintiles.  One cohort was assigned to have optimal 
pharmacological therapy. The second cohort was assigned to have optimal 
pharmacological therapy and to undergo cardiac resynchronization. Follow up 
was performed at one, three, six, nine, twelve and eighteen months and every six 
months thereafter, with a mean duration of 29.4 months (range, 18.0 to 44.7).  
The devices used in the study were a Medtronic InSync or InSync III. They 
provided atrial-based, biventricular stimulation with the use of standard right 
ventricular and Attain (Medtronic) left ventricular leads. The left ventricular lead 
was positioned to stimulate the lateral or posterolateral, left ventricular wall 
transvenously. This was then verified radiographically. The device was set with 
atrial pacing at 60 beats per minute, the interventricular delay at zero, and the 
atrioventricular delay was optimized via echocardiography.  
The study’s primary end point was the time to death from any cause or an 
unplanned hospitalization for a major cardiovascular event and its secondary end 
point was death from any cause (Appendix ?, Table 2). Cleland, et al. (2005) 
found, when compared to optimal pharmacological therapy, the addition of CRT 
had a reduced incidence of death or hospitalizations (39% vs. 55%; hazard ratio, 
0.63; 95% CI, 0.51 to 0.77; p<0.001). When looking at death alone, CRT had a 
lower incidence than optimal pharmacological therapy (20% vs. 30%; hazard 
ratio 0.64; 95% confidence interval, 0.48 to 0.85; p<0.002). 
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In 2006, Cleland et al. (2006) published a report of an extension phase to 
the CARE-HF study previously described above. The extension lasted 
approximately 8 months. It was requested and granted because the original 
study was not powered for mortality and required more time to assess the longer-
term effects of CRT and mortality.   
The primary outcome was all-cause mortality. This was from the time of 
randomization of the original study to the completion of the extension phase. The 
mean follow-up was 37.4 months (median 37.6, IQR 31.5–42.5, range 26.1–52.6 
months). This study continued to show a decreased mortality of the patients 
receiving CRT over that of the optimal pharmacological therapy (hazard ratio 
0.60, 95% CI, 0.47–0.77, p=0.0001). Cleland et al. (2005) concluded that CRT 
reduced complications, reduced the risk of death, and improved symptoms and 
quality of life.  
The secondary outcome that Cleland et al. (2006) considered was mode 
of death.  They found a reduction in the risk of death due to heart failure (64 vs. 
38 deaths; hazard ratio 0.55, 95% CI 0.37–0.82, P=0.003) and sudden death (55 
vs. 32; hazard ratio 0.54, 95% CI, 0.35–0.84, P= 0.005). 
The most recent of the studies, Resynchronization–Defibrillation for 
Ambulatory Heart Failure Trial (RAFT), Tang, et al. (2010) followed 1798 patients 
with a NYHA Class II or III Heart Failure. The inclusion criteria was continued 
heart failure symptoms despite optimal pharmacological treatment, a left 
ventricular EF less than or equal to 30%, an intrinsic QRS duration of 120 msec. 
or a paced QRS duration of 200 msec. or more, sinus rhythm or permanent atrial 
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fibrillation or flutter with a controlled ventricular rate (•60 beats per minute at rest 
and •90 beats per minute during a 6-minute walk test). They excluded patients 
with a major coexisting illness or a recent cardiovascular event. The mean follow 
up was 40 months, completed at one month after device implantation and then 
every six months for a minimum of 18 months. 
In this study, Tang, et al. (2010) compared Implantable Cardioverter 
Defibrillator (ICD) therapy to ICD with CRT. They used commercially available 
transvenous leads and devices. The implantation was done using a standard 
technique with an emphasis on placing the left ventricular lead to the lateral or 
posterolateral wall of the left ventricle. The devices were programmed in a 
manner to minimize ventricular pacing in the ICD group, maximize ventricular 
pacing in the ICD–CRT group.  
The primary outcome was death from any cause, or hospitalization for HF 
(Appendix B,Table 2). The study found a decrease in death and hospitalization 
for the ICD-CRT compared to that of the ICD only group  (0.75; 95% CI, 0.64 to 
0.87; p<0.001). When just looking at mortality, ICD-CRT again showed a 
decreased risk (hazard ratio, 0.75; 95% CI, 0.62 to 0.91; P=0.003).  
The study did note a higher rate of adverse events, 30 days after surgery, 
secondary to implantation of ICD-CRT (124 patients in the ICD-CRT group, and 
58 in the ICD group (p<0.001)). Despite the high rate of adverse events, Tang et 
al. (2010) concluded that adding CRT to an ICD reduced the rates of death and 
hospitalizations for HF. 
DISCUSSION 
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Already a leading cause of hospitalization and deaths in the geriatric 
population, the rate of heart failure will only rise correspondent to the increasing 
numbers of cardiac related diseases like hypertension, coronary artery disease 
and diabetes. Cardiac-Resynchronization Therapy may be a viable option to treat 
this expanding population. A total of three randomized controlled trials and one 
extension trial exploring the benefits of CRT, were reviewed.  
The combined evidence for the outcome of death, in both CRT vs. IDT 
with optimal pharmacological therapy and CRT vs. optimal pharmacological 
therapy is rated ‘Moderate’. To evaluate the strength of evidence for the 
combination of the study’s outcome, Grading of Recommendations Assessment, 
Development and Evaluation (GRADE) (Appendix, D,Table 4) was used.  
As per the inclusion criteria, each of the studies was randomized. This 
sets the starting GRADE as High. None of the reviewed trials stated if their 
randomization was concealed or not. They did include a ‘Table 1’ describing the 
characteristics of the patients at baseline. After reviewing the tables, it appears 
the patients were similar in each cohort and surprisingly, between each of the 
three studies (Appendix C,Table 3) showing ‘Consistency’ between the combined 
studies. 
Evaluating the ‘Directness” of the studies, revealed all three trials with an 
outcome of death. Every one of them also included statistics on the effect on 
hospitalization as an outcome. The earliest of the studies, the COMPANION 
(Bristow et al., 2004) trial compared CRT, both with, and without, an Implantable 
Defibrillator, to that of optimal pharmacological care. The CARE-HF and the 
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CARE-EF Extension Trials compared CRT only to optimal pharmacological care 
(Cleland et al., 2005, 2006). The latest study, the RAFT  (Tang, et al., 2010), 
compared CRT to standard pacemaker therapy, but primarily looked at patients 
with mild HF. No matter the comparison or classification of HF, the combined 
outcome was determined to be ‘Moderate’ in quality and showed a statistically 
significant decrease in the risk of death and/or hospitalizations from cardiac 
events with the use of CRT.  
 Only one of the three studies, the RAFT (Tang et al., 2010), was 
constructed and performed as a double-blind trial. Whereas the COMPANION 
trial (Bristow et al., 2004), only blinded the steering committee and its sponsor. 
Finally, the CARE-HF trial and its extension (Cleland et al., 2005; Cleland et al., 
2006) indicated only the endpoint committee was unaware of the patient’s 
treatment assignment. These latter two studies caused a deduction in the ‘’Study 
Design” category because of this. The author of the COMPANION (Bristow et al., 
2004) trial indicated that this might have caused a larger than expected 
withdrawal from the study. Though, the CARE-HF and its extension did not suffer 
from the same fate (Cleland, 2005; Cleland, 2006). Arguably, their design, 
implantable device vs. none, made blinding impractical and an ethical issue. 
 Follow-up was complete in all three studies. After review, it was noted that 
the COMPANION trial (Bristow et al., 2004) had the lowest follow up time and the 
highest withdrawal rate. Compounding this problem was a difference in the drop 
out rate between, who left, its three patient groups, with the pharmacological 
therapy group having nearly four times the loss rate of the other two cohorts. 
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Though Bristow et al (2004) reported no significant difference between patients, 
who left, with the exception of the prevalence of ischemic cardiomyopathy, 
compared to those that remained till completion (Bristow et al., 2004). This high, 
skewed dropout rate decreased the ‘precision’ of the results in GRADE.  The 
other two trials reported minimal loss to follow up. All of the trials, with the 
exception of the CARE-HF with its extension (Cleland et al., 2005; Cleland et al., 
2006), completed their trials, as scheduled. 
While primarily looking at morbidity and mortality, both the COMPANION 
(Bristow, et al., 2004) and the CARE-HF (Cleland, et al., 2005) evaluated the 
benefits of CRT on cardiac function also. Bristow et al. (2004) found a decrease 
in median blood pressure, an increase in distance walked in six minutes and a 
higher reported quality of life. Cleland et al. (2005) noted an increase in left 
ejection fraction and improved symptoms with an associated increase in quality 
of life. These are import findings and should be explored more thoroughly in the 
future, because an increase in quality of life is probably the most instant and 
tangible factor for the patient.  
A major weakness for all three of the trials was a severe under 
representation of female patients (Appendix C,Table 3). Almost one in every two 
women will die from a cardiovascular disease and HF is the number one killer of 
women (AHRQ, 2009). It would be important to incorporate more women in 
future trials to assess the effect of CRT on this important population. Please also 
include a statement about the overall grade and an explanation of what 
“moderate” means as defined by the GRADE working group. 
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 Each study noted a higher rate of adverse events secondary to the 
implantation process, but all showed a marked decrease in mortality and 
morbidly over that of pharmacologically optimal care. Despite the inherent risks 
with any surgery, let alone a cardiac one, a 65 year old, male patient with 
moderate heart failure, a prolonged QRS, would be a good candidate for CRT 
and should be routinely considered for this treatment option. 
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APPENDIX A 
 
Table 1 
 
   NYHA Heart Failure Symptom Classification 
Class Symptoms 
  I      (Mild) 
• No limitation of physical activity  
• Ordinary physical activity does not cause undue fatigue, 
palpitation, or dyspnea 
  II     (Mild) 
• Slight limitation of physical activity.  
• Comfortable at rest, but ordinary physical activity results 
in fatigue, palpitation or dyspnea 
  III    (Moderate) 
• Marked limitation of physical activity.  
• Comfortable at rest, but less than ordinary activity causes 
fatigue, palpitation, or dyspnea,  
  IV   (Severe) 
• Unable to carry out any physical activity without 
discomfort. 
• Symptoms of cardiac insufficiency at rest. If any physical 
activity is undertaken, discomfort is increased 
(Mann, 2008) 
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APPENDIX B 
 
   Table 2          
Summary of Trials 
Study Comparison Outcome Findings  (Hazard Ratio & 95% CI) 
RAFT 
Tang et al, 2010 CRT vs. ICD 
Death or 
Hospitalization for HF 
↓ Risk of death or hospitalization for HF 
    - Hazard ratio, 0.75; 95% CI, 0.64–0.87; P<0.001 
↓ Risk of death any cause 
    - Hazard ratio, 0.75; 95% CI, 0.62–0.91; P= 0.003 
↓ Risk of hospitalization for HF 
    - Hazard ratio, 0.68; 95%; CI, 0.56–0.83; P<0.001 
CARE-HF 
Cleland et al, 
2005 
CRT vs. 
Pharmacologic 
Therapy 
Death (All cause) or 
an unplanned 
hospitalization for a 
major cardiovascular 
event 
↓ Risk of death or unplanned hospitalization for a cardiovascular event 
     - Hazard ratio, 0.63; 95% CI, 0.51 to 0.77; P<0.001 
↓ Risk of unplanned hospitalization for a cardiovascular event 
     - Hazard ratio, 0.61; 95% CI, 0.49 to 0.77; P<0.001 
↓ Risk of death any cause 
     - Hazard ratio, 0.64; 95% CI, 0.48 to 0.85; P<0.002 
CARE-HF 
(Extension) 
Cleland et al, 
2006 
Extension of 
above trial As Above 
↓ Risk of death any cause 
     - Hazard ratio, 0.60; 95% CI, 0.47–0.77, P=0.0001 
↓ Risk of death due to heart failure  
     - Hazard ratio, 0.55, 95% CI, 0.37–0.82, P=0.003 
COMPANION 
Bristow et al, 
2004 
CRT vs. ICD vs. 
Pharmacologic 
Therapy 
Death or 
Hospitalization for any 
reason 
↓ Risk of death or hospitalization for any cause 
    - CRT:  
        Hazard ratio, 0.81; 95% CI, 0.69 to 0.96; P = 0.014 
    - CRT & Defibrillator:  
         Hazard ratio, 0.80; 95% CI, 0.68 to 0.95; P=0.01 
 21
 
APPENDIX C 
 
Table 3 
Summery of Trial Population 
Study Size 
Population 
(Control/Exposed) 
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(
%
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(
%
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D
I
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COMPANION 
(Bristow et 
al,. 2004) 
1520 68/67
1
 
68/662 
69/671 
69/672 ~ 
82/871 
82/862 
18/131 
18/142 
22/201 
22/222 
158/1601 
158/1602 
59/541 
55/552 
89/891 
89/902 
89/891 
89/902 
55/531 
55/552 
94/941 
94/972 ~ 
CARE-HF 
and 
Extension 
Cleland et al,. 
2005; Cleland 
et al., 2006) 
813 66/67 73/74 ~ 93/94 7/6 25/25 160/160 36/40 95/95 74/70 59/54 44/43 45/40 
RAFT 
(Tang et al,. 
2010) 
1798 66/66 81/85 81/79 19/21 ~ 23/23 158/157 65/69 97/96 89/90 42/42 84/85 35/34 
~ Not reported 
1Optimal pharmacological therapy vs. CRT 
2Optimal pharmacological therapy vs. CRT with implanted deliberator 
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APPENDIX D 
 
Table 4 
Strength of Evidence 
Outcome 
 
Quantity and 
Type of 
Evidence 
Findings 
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D
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R
e
s
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n
s
e
 
C
o
n
f
o
u
n
d
e
r
s
 
Death  
3 RTC 2, 3, 4, 7 
 ↓ Mortality  High -1 0 0 -1 0 +1 0 0 Moderate 
Moderate 
Hospitalization 
3 RTC 2, 3, 4, 7 
↓ Morbidity High -1 0 0 -1 0 +1 0 0 Moderate 
2 Bristow et al., 2004              
3
 Cleland et al., 2005    
4
 Cleland et al., 2006 
7
 Tang et al., 2010 
  
